Loading patent…
AssigneeAcumen Pharmaceuticals, Inc.
InventorsWilliam F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Nigyan Zhang, Wei-Qin Zhao
Estimating the term…
This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
A kit for detecting oligomers of amyloid beta comprising:
An isolated antibody, or antigen binding fragment thereof, that binds amyloid β-derived diffusible ligands, has an affinity for amyloid beta 1-42 oligomers compared to amyloid beta 1-40 monomers in a competitive binding assay of at least 500:1, and has:
An isolated antibody, or antigen binding fragment thereof, that binds amyloid β-derived diffusible ligands, has an affinity for amyloid beta 1-42 oligomers compared to amyloid beta 1-40 monomers in a competitive binding assay of at least 500:1, and has:
An isolated antibody, or antigen binding fragment thereof, that binds amyloid β-derived diffusible ligands comprising:
Dependencies are inferred from the claim text.